EUDA推出基因调节补充剂;上市前股价上涨

2025-08-26 21:43

Shares of EUDA Health Holdings (NASDAQ:EUDA) rose 10% in the premarket trade on Tuesday after the company announced that it has secured exclusive global distribution rights for a next-generation immune health supplement from Singapore biotech, Chemokine Pte. Ltd.
Euda Helixé, the supplement, uses epigenetic gene modulation to boost metabolism, energy, skin regeneration, and longevity.
Initial sales will focus on Singapore, Malaysia, and China, with plans to expand globally.
Company targets 500,000 unit sales over the next 12 months.
The product was developed by Prof. Kah Meng Lim, a molecular medicine expert, formerly with Singapore's national R&D agency, A*STAR.
"The Supplement positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology. " CEO Alfred Lim, said in a statement.
EUDA +10.48% premarket to $2.95
Source: Press Release

More on EUDA Health Holdings Limited